Cell budding from normal appearing epithelia: A predictor of colorectal cancer metastasis?

International Journal of Biological Sciences

Volumn 9, Issue 1, 2013, Pages 119-133

  Jiang, Bin ^a   Mason, Jeffrey ^b   Jewett, Anahid ^c   Qian, Jun ^a   Ding, Yijiang ^a   Cho, William C S ^d   Zhang, Xichen ^e   Man, Yan Gao ^e,f  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^e JILIN UNIVERSITY   (China)

^f Henry Jackson Foundation   (United States)

Author keywords

Lymphocyte infiltration; Stem cell; Tumor capsule; Tumor invasion; Tumor metastasis

Indexed keywords

ARTICLE; COLORECTAL TUMOR; HUMAN; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; STEM CELL.; TUMOR CAPSULE; TUMOR INVASION;

LYMPHOCYTE INFILTRATION; STEM CELL.; TUMOR CAPSULE; TUMOR INVASION; TUMOR METASTASIS;

COLORECTAL NEOPLASMS; HUMANS; LYMPHOCYTES; NEOPLASM METASTASIS;

ANIMALIA;

EID: 84872836286     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5441     Document Type: Article

References (98)

1. de Wijkerslooth TR, Bossuyt PM, Dekker E. Strategies in screening for colon carcinoma. Neth J Med. 2011; 69(3):112-9.
2. Cummings LC, Cooper GS. Colorectal cancer screening: update for 2011. Semin Oncol. 2011; 38(4):483-9.
3. Vu HT, Burke CA. Advances in colorectal cancer screening. Curr Gastroenterol Rep. 2009; 11(5):406-12.
4. Zhou MG, Wang XF, Hu JP, et al. Geographical distribution of cancer mortality in China, 2004-2005. Zhonghua Yu Fang Yi Xue Za Zhii. 2010; 44(4):303-8.
5. Lei T, Chen WQ, Zhang SW, et al. Prevalence trend of colorectal cancer in 10 cities and counties in China from 1988 to 2002. Zhonghua Zhong Liu Za Zhi. 2009; 31(6):428-33.
6. Mahmodlou R, Mohammadi P, Sepehrvand N. Colorectal cancer in northwestern Iran. ISRN Gastroenterol. 2012;:968560.
7. Shin A, Joo J, Bak J, et al. Site-specific risk factors for colorectal cancer in a Korean population. PLOS One. 2011; 6(8):e23196.
8. Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012; 4(4):71-5.
9. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010; 24(4):381-96.
10. Michor F, Iwasa Y, Rajagopalan H, et al. Linear model of colon cancer initiation. Cell Cycle. 2004; 3(3):358-62.
11. Aaltonen LA. The multistep process of colon carcinogenesis. Cytokines Mol Ther.1996;2(2):111-4.
12. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA. 2002; 99(23):15095-100.
13. Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther, 2009; 9(12):1829-47.
14. Shimada H, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg.2009; 394(6):973-83.
15. Ernst M, Ramsay RG. Colorectal cancer mouse models: integrating inflammation and the stroma. J Gastroenterol Hepatol. 2012; 27(1):39-50.
16. Sussman DA, Santaolalla R, Strobel S, et al. Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol. 2012; 28(4):327-33
17. Roper J, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci. 2012; 33(8):449-55.
18. Labianca R, Merelli B. Screening and diagnosis for colorectal cancer: present and future. Tumori. 2010; 96(6):889-901.
19. Chen SL, Steele SR, Eberhardt J, et al. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg 2011; 253(1):82-7.
20. Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol. 2012; 47(3):296-314.
21. Mathis KL, Larson DW, Dozois EJ, et al. Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg. 2012; 99(1):137-43. doi: 10.1002/bjs.7739.
22. Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull. 2010; 94:49-64.
23. Gerges N, Jabado N. Biomarkers in cancer micrometastasis: where are we at? Bioanalysis. 2010; 2:881-99.
24. Mahmoud W, Sukhanova A, Oleinikov V, et al. Emerging applications of fluorescent nanocrystals quantum dots for micrometastases detection. Proteomics. 2010; 10(4):700-16.
25. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007; 12(4):418-25.
26. Man YG, Sang QXA. The significance of focal myoepitehlial cell layer disruptions in breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Exp Cell Res. 2004;301:103-18.
27. Yousefi M, Mattu R, Gao C, Man YG. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion. AIMM 2005; 13:30-7.
28. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev. 2005; 29:161-9.
29. Man YG, Tai L, Barner R, et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res. 2003; 5: R231-41.
30. Man YG, Zhang Y, Shen T, et al, et al. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat. 2005; 89:199-208.
31. Man YG, Fu S, Liu AJ, et al. Aberrant expression of chromogranin A, mir-146a, and mir-146b-5p in prostate structures with focally disrupted basal cell layers: an early sign of invasion and hormone-refractory cancer? Cancer Genom & Proteom. 2011; 8(5): 235-44.
32. Man YG. Focal degeneration of aged or injured myoepithelial cells and the resultant auto-immunoreactions are trigger factors for breast tumor invasion. Med Hypoth. 2007; 69(6):1340-57.
33. Man YG, Gardner WA. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Med Hypoth. 2008; 70:387-408.
34. Man YG. Tumor cell budding from focally disrupted tumor capsules: a common pathway for all breast cancer subtype derived invasion? J Cancer. 2010; 1: 27-31.
35. Man YG. A seemingly most effective target for early detection and intervention of prostate tumor Invasion. J Cancer. 2012; 1: 63-69.
36. Man YG, Harley R, Mason J, Gardner WA. Contributions of leukocytes to tumor invasion and metastasis: the "piggy-back" hypothesis. Cancer Epidem. 2012; 34(1): 3-6.
37. Man YG, Mason J, Harley R, et al. Leukocyte-facilitated tumor dissemination: findings from multiple types of human tumors. J Cell Biochem. 2011; 112 (4):1154-67.
38. Neeson PJ, Thurlow PJ, Jamieson GP. Characterization of activated lymphocyte-tumor cell adhesion. J Leukoc Biol. 2000; 67(6):847-55.
39. Neeson PJ, Thurlow PJ, Jamieson GP, Bradley C. Lymphocyte-facilitated tumour cell adhesion to endothelial cells: the role of high affinity leucocyte integrins. Pathology. 2003;35(1):50-5.
40. Bakker GJ, Eich C, Torreno-Pina JA, et al. Lateral mobility of individual integrin nanoclusters orchestrates the onset for leukocyte adhesion. Proc Natl Acad Sci USA. 2012;109(13): 4869-74.
41. Moinfar F, Man YG, Arnould L, et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis. Cancer Res. 2000; 60: 2562-6.
42. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells 2012, 30(3):363-71.
43. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012; epub.
44. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011; 71(3):634-9.
45. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6(4):281-91.
46. Min Hu and Kornelia Polyak. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. February 2008; 18(1): 27-34.
47. Puspa Raj Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Front Biosci. 2011; 15: 226-36.
48. Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 1986; 12(4):294-307
49. Noffsinger A, Fenoglio-Preiser CM, Maru D, Gilinsky N. Gastrointestinal Diseases. Washington DC: American Registry of Pathology and Armed Forces Institute of Pathology. 2007.
50. Lazaris ACh, Tzoumani AN, Thimara I, et al. Immunohistochemical assessment of basement membrane components in colorectal cancer: prognostic implications. J Exp Clin Cancer Res. 2003; 22(4):599-606.
51. Ambiru S, Miyazaki M, Ito H, et al. Type IV collagenase activities in human colorectal cancers and its role in cancer invasion and metastasis. Nihon Shokakibyo Gakkai Zasshi. 1993;90(7):1555-61.
52. Hagedorn EJ, Sherwood DR. Cell invasion through basement membrane: the anchor cell breaches the barrier. Curr Opin Cell Biol. 2011; 23(5):589-96.
53. Bayar S, Saxena R, Emir B, Salem RR. Venous invasion may predict lymph node metastasis in early rectal cancer. Eur J Surg Oncol. 2002; 28(4):413-7.
54. An JY, Baik YH, Choi MG, et al. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Ann Surg. 2007; 246(5):749-53.
55. Rasheed S, Bowley DM, Aziz O, Tekkis PP, Sadat AE, Guenther T, et al. Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. Colorectal Dis 2008,10(3):231-8.
56. Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008; 38(10):905-10.
57. Tateishi Y, Nakanishi Y, Taniguchi H, Shimoda T, Umemura S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pahtol. 2010; 23(8):1068-72.
58. Huh JW, Kim HR, Kim YJ. Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J Gastrointest Surg. 2010;14(7):1074-80.
59. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010; 1(7):651-61.
60. Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008; 51(5):568-72.
61. Ogawa T, Yoshida T, Tsuruta T, et al. Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths. Scand J Gastroenterol. 2009; 44(5):605-14.
62. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1):134-41.
63. Märkl B, Renk I, Oruzio DV, et al. Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol. 2010; 102(3):235-41.
64. Glasgow SC, Bleier JI, Burgart LJ, Finne CO, Lowry AC. Meta-analysis of Histopathological Features of Primary Colorectal Cancers that Predict Lymph Node Metastases. J Gastrointest Surg. 2012; 16(5):1019-28
65. Jiang B, Mason J, Jewett A, Cho WC, Man YG. Tube-like structures with co-expression of D2-40 and CD34: newly formed vasculatures? Int J Biol Sci.2012;8(8):1206-16.
66. Bin Jiang, Yan-gao Man, Anton Bilchik, et al. Differential lymphatic involvement in primary site of node positive and negative colorectal cancer. Manuscript in the process for submission.
67. Michel M, Török N, Godbout MJ, et al Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci. 1996; 109(Pt 5):1017-28.
68. Larouche D, Hayward C, Cuffley K, Germain L. Keratin 19 as a stem cell marker in vivo and in vitro. Methods Mol Biol 2005; 289:103-10.
69. Naujok O, Francini F, Jörns A, Lenzen S. An efficient experimental strategy for mouse embryonic stem cell differentiation and separation of a cytokeratin-19-positive population of insulin-producing cells. Cell Prolif. 2008; 41(4):607-24.
70. Larouche D, Lavoie A, Paquet C, Simard-Bisson C, Germain L. Identification of epithelial stem cells in vivo and in vitro using keratin 19 and BrdU. Methods Mol Biol. 2010; 585:383-400.
71. Chang CC, Yang SH, Chien CC, et al. Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer. 2009; 9:376.
72. Yang SH, Huang CJ, Lee CL, et al. Fecal RNA detection of cytokeratin 19 and ribosomal protein L19 for colorectal cancer. Hepatogastroenterology. 2010; 57(101):710-5.
73. Sun GR, Dong XY, He QS, Qu H, Wang YM. Expression and clinical significance of CK19 and CK20 expressions in transverse mesocolon biopsies from patients with gastric carcinoma. Cell Biochem Biophys. 2012; 62(2):361-4.
74. Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011; 54(5):1707-17.
75. Roy S, Majumdar AP. Signaling in colon cancer stem cells. J Mol Signal. 2012; 7(1):11.
76. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8.
77. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7):3983-8.
78. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA. 2003;100(7):3547-9.
79. Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 2012; 45(1):98-103.
80. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA. 2010;107(8):3722-7.
81. Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Patho. 2011;64:937-46.
82. Wang B, Jacob ST. Role of cancer stem cells in hepatocarcinogenesis. Genome Med. 2011; 3(2): 11.
83. Johnston MD, Maini PK, Jonathan Chapman S, et al. On the proportion of cancer stem cells in a tumour. J Theor Biol. 2010; 266(4):708-11.
84. Smith LG, Weissman IL, Heimfeld S. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc. Natl. Acad. Sci. USA. 1991; 88:2788-92.
85. Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenot'ype but not function. Blood. 1995; 85:1006-1016.
86. Offner F, Kerre T, DeSmedt M, Plum J. Bone marrow CD34+ cells generate fewer T cells in vitro with increasing age and following chemotherapy. Bri J Haematology. 1999;104:801-8.
87. Osawa M, Hanada K-i, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996; 273:242-5.
88. Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J. Exp. Med. 2000; 192:1273-80.
89. Liang Y, Van Zant G. Genetic control of stem-cell properties and stem cells in aging. Curr Opin Hematol. 2003;10:195-202.
90. Liang Y, Van Zant G. Aging stem cells, latexin, and longevity. Exp Cell Res. 2008; 314(9):1962-72.
91. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells. 2012; 30(3):363-71.
92. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev. Gastroenterol Hepatol. 2011; 8(2):90-100.
93. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012; [Epub ahead of print].
94. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011; 71(3):634-9.
95. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (Clinging ductal carcinoma in situ)-A simulator of normal mammary epithelium. Cancer. 2000; 88:2072-81.
96. Malins DC, Gilman NK, Green VM, et al. A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA. 2005; 102: 19093-6.
97. Lazaris AC, Tzoumani AN, Thimara I, et al. Immunohistochemical assessment of basement membrane components in colorectal cancer: prognostic implications. J Exp Clin Cancer Res. 2003; 22(4):599-606.
98. Alga AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Onco. 2012; Epub.